US focuses pharma supply chain scrutiny


The US Food and Drug Administration (FDA) has named 13 companies that will be allowed to import drug products into the US with reduced scrutiny. Each company will be permitted to import up to five products under expedited entry arrangements for a period of two years.

The FDA’s Secure Supply Chain Pilot Program is an effort to free up the agency’s resources to focus on areas where imports pose the greatest risk to patients and consumers. The scheme rewards manufacturers for voluntarily adopting best practice and integrating integrity and security into their supply chain operations.

The move comes in the wake of a string of product recalls and import bans as some elements of the pharma industry struggle to maintain appropriate quality standards.


Related Content

Reaching out

22 May 2014 Premium contentFeature

news image

Andy Extance surveys how pharma uses outsourcing in a variety of different ways

Business roundup

28 March 2012 Business

news image

Industry news, April 2012

Most Read

Magnetic resonance taken to the limit

21 November 2014 Research

news image

Technique can read the spin of a single nucleus opening up a new way to investigate proteins and complex molecules

Boron and beryllium finally shake hands

24 November 2014 Research

news image

Never-before-seen bond observed between periodic table neighbours

Most Commented

US approves low acrylamide spud

25 November 2014 News and Analysis

news image

The first genetically modified potato that produces less acrylamide has been granted approval in the US

Nanostripe controversy in new twist

24 November 2014 Research

news image

Creator of striped nanoparticles insists questions over structures have already been answered and accuses critics of a 'perso...